

Brendon L Neuen Mbbs

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2048762/brendon-l-neuen-mbbs-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47
papers

1,302
citations

17
h-index

36
g-index

54
ext. papers

2,191
ext. citations

7.9
avg, IF

4.83
L-index

#	Paper	IF	Citations
47	Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data From Randomized Controlled Trials.. <i>Circulation</i> , 2022 ,	16.7	8
46	Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People With and Without Diabetes.. <i>Advances in Chronic Kidney Disease</i> , 2021 , 28, 298-308	4.7	0
45	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	0
44	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1652-1659	6.7	3
43	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. <i>Circulation</i> , 2021 , 143, 1735-1749	16.7	19
42	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis. <i>Stroke</i> , 2021 , 52, 1545-1556	6.7	11
41	Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey. <i>BMJ Open</i> , 2021 , 11, e047245	3	3
40	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. <i>International Journal of Cardiology</i> , 2021 , 324, 165-172	3.2	2
39	Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 382-390	6.7	20
38	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 23-34.e1	7.4	12
37	Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 252-257	6.7	2
36	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. <i>ESC Heart Failure</i> , 2021 , 8, 1482-1493	3.7	4
35	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 384-395	6.9	12
34	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021 ,	9.5	22
33	Chronic kidney disease. <i>Lancet, The</i> , 2021 , 398, 786-802	40	73
32	Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA, disease duration and treatment intensity: results from the CANVAS Program. <i>Diabetologia</i> , 2021 , 64, 2402-2414	10.3	2
31	Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. <i>Diabetologia</i> , 2021 , 64, 2147-2158	10.3	9

30	Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression. <i>American Journal of Kidney Diseases</i> , 2021 , 78, 350-360.e1	7.4	5
29	Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 ,	6.9	3
28	Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e021661	6	2
27	Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. <i>Kidney International</i> , 2020 , 98, 769-777	9.9	26
26	The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1753-1766	6.7	8
25	Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020 , 9, e014908	6	97
24	Risk Factors for Incident Kidney Disease in Older Adults: an Australian Prospective Population-Based Study. <i>Internal Medicine Journal</i> , 2020 ,	1.6	2
23	Availability, coverage, and scope of health information systems for kidney care across world countries and regions. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	3
22	Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, i48-i55	4.3	9
21	Lupus nephritis in Indigenous Australians: a single-centre study. <i>Internal Medicine Journal</i> , 2020 , 50, 830-837	0.7	0
20	Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 903-914	18.1	34
19	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Analysis from the CREDENCE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 2925-2936	12.7	30
18	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 845-854	18.1	335
17	Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1237-1250	6.7	114
16	Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. <i>BMJ, The</i> , 2019 , 367, l5873	5.9	55
15	A longitudinal faculty development program: supporting a culture of teaching. <i>BMC Medical Education</i> , 2019 , 19, 400	3.3	6
14	Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. <i>Cmaj</i> , 2019 , 191, E1128-E1135	3.5	13
13	Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , 2019 , 171, 181-189	8	44

12	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 2229-2242	12.7	57
11	Reducing cardiovascular risk in people with diabetes and kidney disease. <i>Medical Journal of Australia</i> , 2018 , 209, 438-439	4	
10	Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. <i>Circulation</i> , 2018 , 138, 1537-1550	16.7	149
9	Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in Far North Queensland Australian adults. <i>Nephrology</i> , 2017 , 22, 520-530	2.2	2
8	Neutrophil-lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients. <i>Renal Failure</i> , 2016 , 38, 70-6	2.9	24
7	Endovascular Stent Placement for Hemodialysis Arteriovenous Access Stenosis. <i>International Journal of Vascular Medicine</i> , 2015 , 2015, 971202	1.2	2
6	Factors associated with patency following angioplasty of hemodialysis fistulae. <i>Journal of Vascular and Interventional Radiology</i> , 2014 , 25, 1419-26	2.4	23
5	Regarding "Prospective, randomized study of cutting balloon angioplasty versus conventional balloon angioplasty for the treatment of hemodialysis access stenoses". <i>Journal of Vascular Surgery</i> , 2014 , 60, 1122	3.5	1
4	Balloon inflation time in angioplasty of dialysis access stenosis. <i>Hemodialysis International</i> , 2014 , 18, 847-87		
3	Predictors of patency after balloon angioplasty in hemodialysis fistulas: a systematic review. <i>Journal of Vascular and Interventional Radiology</i> , 2014 , 25, 917-24	2.4	47
2	Global kidney disease. <i>Lancet, The</i> , 2013 , 382, 1243	40	1
1	Diagnostic test studies in nephrology: quantity, quality, and scope. <i>American Journal of Kidney Diseases</i> , 2011 , 58, 921-7	7.4	2